MannKind Corp: A Connecticut-based biopharmaceutical firm specializing in diabetes and pulmonary treatments.
MannKind Corporation, founded in February 1991 and based in Danbury, Connecticut, is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutic products. The company's core mission is to improve the lives of people living with endocrine and orphan lung diseases, particularly focusing on diabetes and pulmonary arterial hypertension. MannKind leverages cutting-edge technology and a solutions-based approach to deliver effective treatments and devices that enhance patient outcomes.
Notable figures associated with MannKind include its founder, Alfred E. Mann, a renowned entrepreneur in the medical device industry. The company has achieved significant milestones, including the development and commercialization of Afrezza, an inhalable insulin product for diabetes management. MannKind's impact is evident in its commitment to advancing medical science and improving the quality of life for patients with chronic conditions. The company's innovative approach and dedication to patient care have positioned it as a key player in the biopharmaceutical industry.

Insulet
insulet.com

Manhattan Pharmaceuticals

Tandem Diabetes Care
tandemdiabetes.com

Novo Nordisk
novonordisk.com

Sensulin
sensulin.com

Ascensia Diabetes Care
ascensia.com

Pulmatrix
pulmatrix.com

United Therapeutics

Insmed
insmed.com

Exsulin

Thermalin
Lung Biotechnology
unither.com

Beta Bionics

Dexcom
dexcom.com

Vivus
vivus.com
Companies similar to MannKind include Insulet, Manhattan Pharmaceuticals, Tandem Diabetes Care and Novo Nordisk.
MannKind was founded in 1991.
MannKind's headquarters is located in Danbury, CT, US.
MannKind has 233 employees as of Feb 6, 2024.